抗人前列腺干细胞抗原单克隆抗体可变区基因的5＇RACE扩增及序列分析

目的：克隆并分析抗人前列腺干细胞抗原单克隆抗体轻链和重链的可变区基因。方法：从分泌抗人前列腺干细胞抗原单克隆抗体的杂交瘤细胞株中提取总RNA,根据小鼠IgG恒定区序列设计特异性引物,通过5’RACE法扩增其轻链和重链的可变区基因,克隆入pMD18-T载体,测序并分析其可变区序列。结果：3株抗人前列腺干细胞抗原单克隆抗体的重链可变区基因序列全长均为423bp,编码141个氨基酸残基;轻链可变区基因序列全长均为393bp,编码131个氨基酸残基;在GenBank中对氨基酸序列进行比对分析,均符合小鼠IgG可变区基因的特征;根据Kabat法则对3株抗体轻链和重链可变区氨基酸序列进行分析,确定了3个抗原互补决定区、4个框架区和前导肽。结论：通过5＇RACE法得到了3株抗人前列腺干细胞抗原单克隆抗体轻链与重链可变区基因,为进一步研究抗体三维结构、人源化改造奠定了基础。     

β淀粉样肽单克隆抗体可变区基因的5′RACE扩增及序列分析

目的:克隆并分析抗β淀粉样肽单克隆抗体轻链与重链可变区基因。方法:从分泌抗β淀粉样肽单克隆抗体的杂交瘤细胞株A8中提取总RNA,根据恒定区序列设计基因特异性引物,通过5′RACE法扩增抗体的轻链和重链可变区基因,测定并分析可变区基因序列,并克隆入pMD18-T载体。结果:重链可变区基因序列全长450bp,编码150个氨基酸残基;轻链可变区基因序列全长429bp,编码143个氨基酸残基。在GeneBank中对氨基酸序列进行比对分析,二者均符合小鼠IgG可变区基因的特征。根据Kabat法则对A8抗体轻链和重链可变区氨基酸序列基因进行分析并确定了3个抗原互补决定区(CDR)、4个框架区(FR)和信号肽。结论:通过5′RACE法得到了抗β淀粉样肽单克隆抗体轻链与重链可变区基因,为进一步研究抗体三维结构,以及对该抗体进行人源化改造奠定了基础。     

二硫键稳定的抗肝癌人源化Fv-突变体人TNFα融合基因的构建与表达

利用引物PCR和重叠延伸PCR法,将抗肝癌人源化抗体hscFv25重链可变区和轻链可变区各定点突变出一个半胱氨酸,将hTNFα改造成高抗肿瘤活性的突变体,分别原核表达重链可变区突变体、轻链可变区突变体-突变体hTNFα融合基因,然后将两种表达的产物混合进行复性,目的获得具有高稳定性和高抗肿瘤活性的抗肝癌靶向细胞因子.结果重链可变区突变体和轻链可变区突变体-突变体hTNFα融合基因在大肠杆菌中均获得高效表达.表达产物以包涵体形式存在,混合复性结果未获得活性产物.     

二硫键稳定的抗肝癌人源化Fv—突变人TNFα融合基因的构建与表达

利用引物PCR和重叠延伸PCR法,将抗肝癌人源化抗体hscFv25重链可变区和轻链可变区各定点突变出一个半胱氨酸,将hTNFα改造成高抗肿瘤活性的突变体,分别原核表达重链可变区突变体,轻链可变区突变体-突变体hhTNFα融合基因,然后将两种表达的产物混合进行复性,目的获得具有高稳定性和高抗肿瘤活性的抗肝癌靶向细胞因子。结果重链可变区突变体和轻链可变区突变体-突变体hTNFα融合基因在大肠杆菌中均获得高效表达,表达产物以包涵体形式存在,混合复合结果未获得活性产物。     

抗人血管内皮生长因子单链抗体基因的构建、表达及活性鉴定

鼠单克隆抗体E11能与人血管内皮生长因子(VEGF)特异结合,已用于临床检测恶性肿瘤细胞VEGF的表达,并初步证明其体内抑瘤活性。为便于大规模生产,特进行基因工程改造,构建小分子的单链抗体(scFv)。首先通过逆转录及多聚酶链式反应(PCR),分离并克隆E11的可变区基因。经测序表明,E11轻链可变区(VL)基因全长333bp,编码111个氨基酸,归属小鼠轻链可变区基因第Ⅲ亚组。重链可变区VH基因全长369bp,编码123个氨基酸,归属小鼠重链可变区基因Ⅱ(A)亚组。然后用一编码亲水性多肽接头的DNA片断将E11单抗轻、重链可变区基因连接,构建表达质粒pET-15YV,在大肠杆菌BL21(DE3)中进行表达。表达产物(包含体)经变性及复性后,用免疫组化法检测该单链抗体结合抗原(颊癌)能力。对颊癌组织检测的结果表明,基因工程抗体scFv与亲代抗体一样,具有较高的组织特异性。本研究获得的抗人VEGF单链抗体具有潜在的临床价值,为肿瘤放射免疫显像及以血管为靶标的抗血管生成治疗奠定了基础。     

抗人肺腺癌单克隆抗体重,轻链可变区基因的分离克隆和序列测定

根据鼠免疫球蛋白重。轻链可变区基因ＦＲ１和ＦＲ４的序列保守性,化学合成了适于体外扩增Ｉｇ重、轻链可变区基因（Ｖ_Ｈ和Ｖ_Ｌ）的数对引物。以分泌抗人肺腺癌单抗的杂交瘤细胞株ＷＬＡ－２Ｃ４的基因组ＤＮＡ为模板,ＰＣＲ扩增Ｖ_Ｈ和Ｖ_Ｌ基因,分别克隆人ｐＵＣ１９载体。转化子经蓝、白斑筛选,酶切鉴定,双脱氧测序证实确为鼠单抗可变区基因,其中Ｖ_Ｈ基因全长为３４８ｂｐ,编码１１６ａａ,属重链ⅡＢ亚类;Ｖ_Ｌ基因全长３１８ｂｐ,编码１０６ａａ,属Ｋ轻链Ⅵ亚类。     

甲型H1N1流感病毒血凝素单克隆抗体轻链和重链可变区基因的巢式PCR扩增及序列分析

目的：采用巢式PCR对甲型H1N1流感病毒血凝素单克隆抗体的轻链和重链基因进行扩增,对获得的基因进行序列分析,并找出克隆鼠Igκ轻链和重链可变区基因的通用方法。方法：设计22对扩增鼠Igκ轻链可变区和重链可变区基因的引物,对6株鼠抗人甲型H1N1流感病毒血凝素单克隆抗体的轻链和重链可变区基因进行克隆并测序,与NCBI公布的鼠免疫球蛋白序列比对分析。结果：巢式PCR方法可以有效避免单克隆抗体克隆过程的假基因,并且得到的单克隆抗体的氨基酸序列均符合鼠免疫球蛋白可变区特征。结论：建立了克隆鼠免疫球蛋白轻链和重链可变区基因的通用方法,为后期克隆鼠源性单克隆抗体的可变区基因提供了基础,并为研究甲型H1N1流感病毒血凝素与抗体的结合位点提供了实验数据。     

鼠抗HFRSV衣壳蛋白McAb F3株可变区基因的获取及特性分析

培养鼠抗肾综合征出血热病毒衣壳蛋白Ｆ３杂交瘤细胞株,提取总ＲＮＡ,根据鼠源ＩｇＧ抗体基因家族可变区基因碱基序列的特点,设计简并引物,通过逆转录聚合酶链反应,获得抗体轻链可变区和重链可变区基因。分别将其克隆入载体ＰＴ７ＢｌｕｅＴ Ｖｅｃｔｏｒ,选取阳性重组克隆各两个,分别测定了所载重链可变区和轻链可变区基因的碱基序列,比较了不同克隆轻链可变区基因之间和重链可变区基因之间碱基序列的差异;分析了各自的氨基酸框架及其对应蛋白的亲水性。结果显示,两个重链可变区基因碱基序列有４处不同,同源性为９７９％;其中重组克隆ＺＧ３６４ ５Ｆ所载重链可变区基因有完整的开放阅读框架,对应的蛋白含有丰富的亲水基因,第１１２氨基酸处亲水性最高;另一重组克隆ＺＧ３６４ ４Ｆ所载重链可变区基因不能通读。两个轻链基因碱基序列有４处不同,同源性为９９１％,重组克隆ＺＧ３６５ ５Ｆ和ＺＧ３６５ ７Ｆ所载轻链可变区基因均有完整的开放阅读框架,对应的蛋白均含有丰富的亲水基因,ＺＧ３６５ ５Ｆ所载基因对应蛋白第６７氨基酸亲水性最高,ＺＧ３６５ ７Ｆ所载基因对应蛋白第３４氨基酸亲水性最高。     

抗人CD3单抗重、轻链可变区基因的体外扩增、克隆和序列分析

根据免疫球蛋白重链和轻链可变区基因５’端序列和Ｊ区序列,化学合成适合于体外扩增抗体重、轻链可变区基因的二对引物。从体外培养的ＯＫＴ３杂交瘤细胞中提取总ＲＮＡ,反转录生成ｃＤＮＡ,以ｃＤＮＡ为模板,分别加入合成的重、轻链可变区引物进行ＰＣＲ,扩增出抗体重、轻链可变区基因片段。将扩增产物分别插入ｐＵＣ１９质粒,筛选出阳性克隆,用链终止法进行ＤＮＡ序列测定。所测重链可变区基因全长３５７ｂｐ,编码１１９个氨基酸,轻链可变区基因全长３２１ｂｐ,编码１０７个氨基酸。     

小鼠(BALB/c）未分化型免疫球蛋白重链可变区(VH）基因的克隆

我们曾报道了由小鼠胎儿基因文库中克隆 未分化型免疫球蛋白重链恒定区CE基因的 研究结果〔3,。与此同时我们还从小鼠基因文库 中克隆出未分化型免疫球蛋白重链可变区VH 基因。并对其进行了初步的研究。免疫球蛋白 的重链和轻链可变区的空间叠折形成了抗原－ 抗体结合位点,这对于结合特异抗原具有重要 作用[1,27。因此克隆与研究免疫球蛋白可变区基 因对于认识抗体的特异性、多样性都有一定的 意义汇‘,‘,。     

The BALB/c secondary response to the Sb site of influenza virus hemagglutinin. Nonrandom silent mutation and unequal numbers of VH and Vk mutations

We have determined the nucleotide sequences of the expressed VH and Vk genes from 13 secondary (2 degrees) hemagglutinin (HA) (Sb) specific hybridomas derived from a single mouse. These antibodies share an Id, H37-68 (68Id) that dominates the 2 degrees HA(Sb) response in this mouse, but is rare or absent from 2 degrees responses of other mice. We find that these antibodies derive from five clones. The H chains of these antibodies are encoded by a single VH gene joined to a variety of DH and JH genes. The length of complementarity-determining region (CDR) 3 and sequence of the D-J junction are restricted, suggesting selection on CDR3 of the H chain. The L chains are more diverse. In the presented examples, they are encoded by the Vk21C and Vk21E genes and a Vk9 gene, and are joined to Jk1, 2, or 4. Each antibody is extensively mutated. The nature and distribution of the mutations suggests that 68Id-producing cells have been selected by Ag, although there are differences regarding the domain (VH, Vk, or both) in which mutations were selected. The implications of these findings on the idiosyncratic nature of the 68Id antibody response to HA(Sb) are discussed. There are two unusual characteristics regarding somatic mutation in these hybridomas. Whereas the expressed VH and Vk21 genes appear to have accumulated mutations at a high rate (1 to 1.5 x 10(-3)/base pairs/division, the expressed Vk9 genes appear to have accumulated mutations at a 5 to 15-fold lower rate than the expressed VH genes in the same cells. There is also a surprisingly high number of parallel silent somatic mutations in the VH genes, of which all but one are clustered to a 28-bp region in framework region 2 and CDR 2-encoding segments. The probability that this could have occurred by a random mutational process is essentially zero.     

Natural mouse and human antibodies bind to a peptide derived from a germline VH chain. Evidence for evolutionary conserved self-binding locus

Murine antibodies derived from the V1 S107/T15 germline structure combined with Vk 22 L chains express the property of self-binding. Previous studies have shown that the self-binding is mediated by the Fab fragment involving structures of the hapten binding site. The molecular locus of self-binding has also been identified by showing that a peptide derived from the CDR2/FR3 region of the V1 S107 H chain inhibits self-binding. We have addressed the question of whether self-binding antibodies interact with peptides that inhibit self-binding. We found that labeled TEPC15 (T15) binds to immobilized VH (50-73) peptide; the peptide binding is specific because different CDR peptides and other unrelated peptides do not inhibit this binding. Furthermore, the hapten phosphorylcholine is a potent inhibitor for the T15-peptide binding. We have demonstrated the presence of naturally occurring antibodies that bind to the T15H(50-73) peptide in the sera of different strains of mice and also in humans, indicating that the CDR2/FR3 sequence of T15 is a conserved Id determining region. We have isolated peptide-specific antibodies from pooled normal human Ig preparations. Human anti-peptide antibodies have self-binding properties similar to their murine counterparts. This interspecies conserved peptide binding of antibodies that are self-binding indicates the existence of an evolutionarily important and biologically active site.     

合作小型猪T细胞受体α链的基因结构及其多样性

目的探讨猪TCR基因分子结构的复杂性及其与人类的相似性。方法以公开的猪TCRα链基因为参考序列设计两对特异性引物,用RT-PCR法从合作小型猪外周血、淋巴结和脾脏的淋巴细胞中克隆了93个猪TCRα基因(简称STA)。结果测序分析表明,克隆的猪TCRα链的基因均含有可变的信号肽区和V区、高变的J区和恒定的C区的基因片段,但基因间的核苷酸序列组成都不完全相同,且具有十分复杂的多态性和多样性,基因间的同源性在68.4%~98.7%,这与TCRα链的基本基因结构特征相一致。依据TCRα基因的同源性对其分子结构、遗传演化关系和归类分析发现,在其信号肽区、FR1区和CDR1区、FR2区和CDR2区以及FR3区和CDR3区都存在一些变异集中点和变异热点区。用IMGT/V-QUEST分析方法可将合作小型猪TCRαV区(STAV)、J区(STAJ)基因片段与人类的进行比较分析,发现合作小型猪TCRα与人类的遗传演化关系较近,每个序列都能找到与人类对应的TRAV、TRAJ基因片段,甚至V区的相似性可达92%以上。结论近交培育的合作小型猪在正常状态具有应对外界复杂微生物等环境的TCR遗传多样性分子基础,且适合作为人类免疫学及疾病研究的动物模型。     

The T cell receptor beta-chain second complementarity determining region loop (CDR2beta governs T cell activation and Vbeta specificity by bacterial superantigens

Superantigens (SAgs) are microbial toxins defined by their ability to activate T lymphocytes in a T cell receptor (TCR) β-chain variable domain (Vβ)-specific manner. Although existing structural information indicates that diverse bacterial SAgs all uniformly engage the Vβ second complementarity determining region (CDR2β) loop, the molecular rules that dictate SAg-mediated T cell activation and Vβ specificity are not fully understood. Herein we report the crystal structure of human Vβ2.1 (hVβ2.1) in complex with the toxic shock syndrome toxin-1 (TSST-1) SAg, and mutagenesis of hVβ2.1 indicates that the non-canonical length of CDR2β is a critical determinant for recognition by TSST-1 as well as the distantly related SAg streptococcal pyrogenic exotoxin C. Frame work (FR) region 3 is uniquely critical for TSST-1 function explaining the fine Vβ-specificity exhibited by this SAg. Furthermore, domain swapping experiments with SAgs, which use distinct domains to engage both CDR2β and FR3/4β revealed that the CDR2β contacts dictate T lymphocyte Vβ-specificity. These findings demonstrate that the TCR CDR2β loop is the critical determinant for functional recognition and Vβ-specificity by diverse bacterial SAgs.     

Molecular cloning of a bovine immunoglobulin lambda chain cDNA

A cDNA library of the bovine mammary gland constructed in pBR322 was screened by mRNA hybrid-selected translation and by differential hybridization. Several immunoglobulin (Ig) lambda light-chain clones were identified and sequenced. Nucleotide sequence comparison of bovine and human Ig lambda chains showed a high degree of homology for constant regions and for J regions. The amino acid (aa) sequence encoded by the constant region of the bovine Ig lambda chain cDNA contains 107 aa with differences at 24 aa positions from the human Ig lambda chain. Three complementarity-determining regions (CDR1,2,3) characteristic of the variable region of bovine Ig lambda chain cDNA can be distinguished. The bovine and human sequences display good homology in the framework region 3 (FR3) but only patches of homology throughout the FR2 region. The 5' end of the bovine Ig lambda chain cDNA fragment of clone 1-14E contains five stop codons: two in CDR1, one in FR1 and two in the hydrophobic prepeptide region. These data suggest that the Ig lambda mRNA of clone 1-14E is transcribed from the V lambda pseudogene.     

Crystal structures of T cell receptor (beta) chains related to rheumatoid arthritis

The crystal structures of the Vbeta17+ beta chains of two human T cell receptors (TCRs), originally derived from the synovial fluid (SF4) and tissue (C5-1) of a patient with rheumatoid arthritis (RA), have been determined in native (SF4) and mutant (C5-1(F104-->Y/C187-->S)) forms, respectively. These TCR beta chains form homo-dimers in solution and in crystals. Structural comparison reveals that the main-chain conformations in the CDR regions of the C5-1 and SF4 Vbeta17 closely resemble those of a Vbeta17 JM22 in a bound form; however, the CDR3 region shows different conformations among these three Vbeta17 structures. At the side-chain level, conformational differences were observed at the CDR2 regions between our two ligand-free forms and the bound JM22 form. Other significant differences were observed at the Vbeta regions 8-12, 40-44, and 82-88 between C5-1/SF4 and JM22 Vbeta17, implying that there is considerable variability in the structures of very similar beta chains. Structural alignments also reveal a considerable variation in the Vbeta-Cbeta associations, and this may affect ligand recognition. The crystal structures also provide insights into the structure basis of T cell recognition of Mycoplasma arthritidis mitogen (MAM), a superantigen that may be implicated in the development of human RA. Structural comparisons of the Vbeta domains of known TCR structures indicate that there are significant similarities among Vbeta regions that are MAM-reactive, whereas there appear to be significant structural differences among those Vbeta regions that lack MAM-reactivity. It further reveals that CDR2 and framework region (FR) 3 are likely to account for the binding of TCR to MAM.     

Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen

The monoclonal IgM cold agglutinins that bind to the I/i carbohydrate Ags on the surface of RBCs all have Ig H chains encoded by the V4-34 gene segment. This mandatory use indicates that distinctive amino acid sequences may be involved in recognition. Critical amino acids exist in framework region 1 (FR1) of V4-34-encoded Ig, and these generate a specific Id determinant which apparently lies close to the I binding site. However, I binding by Id-expressing Ig can be modulated by sequences in complementarity-determining region (CDR)(H)3. Examination of the crystal structure of an anti-I cold agglutinin has revealed a hydrophobic patch in FR1 involving residue W7 on beta-strand A and the AVY motif (residues 23-25) on beta-strand B. In this study we used mutagenesis to show that each of the strand components of the hydrophobic patch is required for binding the I carbohydrate Ag. In addition, the crystal structure reveals that amino acids in the carboxyl-terminal region of CDR(H)3 form a surface region adjacent to the hydrophobic patch. We propose that the I carbohydrate Ag interacts simultaneously with the entire hydrophobic patch in FR1 and with the outside surface of CDR(H)3. This interaction could leave most of the conventional binding site available for binding other Ags.     

Predicting regional mutability in antibody V genes based solely on di- and trinucleotide sequence composition.

Somatic mutations are not distributed randomly throughout Ab V region genes. A sequence-specific target bias is revealed by a defined hierarchy of mutability among di- and trinucleotide sequences located within Ig intronic DNA. Here we report that the di- and trinucleotide mutability preference pattern is shared by mouse intronic JH and Jkappa clusters and by human VH genes, suggesting that a common mutation mechanism exists for all Ig V genes of both species. Using di- and trinucleotide target preferences, we performed a comprehensive analysis of human and murine germline V genes to predict regional mutabilities. Heavy chain genes of both species exhibit indistinguishable patterns in which complementarity-determining region 1 (CDR1), CDR2, and framework region 3 (FR3) are predicted to be more mutable than FR1 and FR2. This prediction is borne out by empirical mutation data from nonproductively rearranged human VH genes. Analysis of light chain genes in both species also revealed a common, but unexpected, pattern in which FR2 is predicted to be highly mutable. While our analyses of nonfunctional Ig genes accurately predicts regional mutation preferences in VH genes, observed relative mutability differences between regions are more extreme than expected. This cannot be readily accounted for by nascent mRNA secondary structure or by a supplemental gene conversion mechanism that might favor nucleotide replacements in CDR. Collectively, our data support the concept of a common mutation mechanism for heavy and light chain genes of mice and humans with regional bias that is qualitatively, but not quantitatively, accounted for by short nucleotide sequence composition.     

Contributions of CDR3 to V H H domain stability and the design of monobody scaffolds for naive antibody libraries

Camelids produce functional antibodies devoid of light chains. Autonomous heavy chain variable (V(H)H) domains in these molecules have adapted to the absence of the light chain in the following ways: bulky hydrophobic residues replace small aliphatic residues in the former light chain interface, and residues from the third complementarity-determining region (CDR3) pack against the framework and stabilize the global V(H)H domain fold. To determine the specific roles of CDR3 residues in framework stabilization, we used nai;ve phage-displayed libraries, combinatorial alanine-scanning mutagenesis and biophysical characterization of purified proteins. Our results indicate that in the most stable scaffolds, the structural residues in CDR3 reside near the boundaries of the loop and pack against the framework to form a small hydrophobic core. These results allow us to differentiate between structural CDR3 residues that should remain fixed, and CDR3 residues that are tolerant to substitution and can therefore be varied to generate functional diversity within phage-displayed libraries. These methods and insights can be applied to the rapid design of heavy chain scaffolds for the identification of novel ligands using synthetic, antibody-phage libraries. In addition, they shed light on the relationships between CDR3 sequence diversity and the structural stability of the V(H)H domain fold.     

Light-chain framework region residue Tyr71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding.

The crystallographic study of chimeric B72.3 antibody illustrated that there are three FR side-chain interactions with either CDR residue's side chain or main chain. For example, hydrogen bonds are formed between the hydroxyl group of threonine at L5 in FR1 and the guanidinal nitrogen group of arginine at L24 in CDR1, between the hydroxyl group of tyrosine at L36 in FR2 and the amide nitrogen group of glutamine at L89 in CDR3 and between the hydroxyl group of tyrosine at L71 in FR3 and the carbonyl group of isoleucine at L29 as well as the amide nitrogen group of serine at L31 in CDR1. Elimination of these hydrogen bonds at these FR positions may affect CDR loop conformations. To confirm these assumptions, we altered these FR residues by site-directed mutagenesis and determined binding affinities of these mutant chimeric antibodies for the TAG72 antigen. We found that the substitution of tyrosine by phenylalanine at L71, altering main-chain hydrogen bonds, significantly reduced the binding affinity for the TAG72 antigen by 23-fold, whereas the substitution of threonine and tyrosine by alanine and phenylalanine at L5 and L36, eliminating hydrogen bonds to side-chain atoms, did not affect the binding affinity for the TAG72 antigen. Our results indicate that the light-chain FR residue tyrosine at L71 of chimeric B72.3 antibody plays an important role in influencing the TAG72 antigen binding. Our results will thus be of importance when the humanized B72.3 antibody is constructed, since this important mouse FR residue tyrosine at L71 must be maintained.